DUSA Pharmaceuticals Inc. has failed to receive orphan drug designation from the FDA for its Levulan Photodynamic Therapy (PDT) system for multiple medical indications, with a concentration on dermatology. As a result, the company will close out the its associated pilot clinical trial.
Posted over 1 year ago
Nanocrystals make dentures shine
Research team develops advanced live-imaging approach (w/ video)
Tunable nano-suspensions for light harvesting
Tagging tumors with gold: Scientists use gold nanorods to flag brain tumors
Laser Hardware/Control Software Engineer I (209) - Hanscom AFB, MA
Postdoctoral Position - La Jolla, CA
Research Engineer position in Super-resolution microscopy - Castelldefels (Barcelona), Spain
Physicist/Physical Chemist/Research Engineer (We Sponsor Clearances) - Lexington, MA
AACR 103rd Annual Meeting 2012
Conference on Lasers and Electro-Optics and the...
